SC 13D

Securities and Exchange Commission,

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

TRINITY BIOTECH plc

(Name of Issuer)

American Depository Shares
Represented by American Depository Receipts
(each representing 4 “A” Ordinary Shares,
par value $0.0109)
(Title of Class of Securities)

89643830
(CUSIP Number)

Thomas J. Reidy
211 May Apple Way
Landrum, SC 29356
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

With copy to:
William M. Schutte, Esq.
Polsinelli Shalton Flanigan Suelthaus PC
6201 College Blvd., Suite 500
Overland Park, KS 66211
(913) 451-8788

October 6, 2008
(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of § 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.       o

NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1	NAMES OF REPORTING PERSONS: Thomas J. Reidy
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
	(a)   o
	(b)   þ
3	SEC USE ONLY
4	SOURCE OF FUNDS (SEE INSTRUCTIONS):
	Not Applicable
5	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
	o
6	CITIZENSHIP OR PLACE OF ORGANIZATION:
	United States
		7	SOLE VOTING POWER
NUMBER OF			0
SHARES		8	SHARED VOTING POWER
BENEFICIALLY
OWNED BY			See Item 5
EACH		9	SOLE DISPOSITIVE POWER
REPORTING
PERSON			101,000
WITH		10	SHARED DISPOSITIVE POWER
			0
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	See Item 5
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
	o
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
	See Item 5
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
	IN

1	NAMES OF REPORTING PERSONS: Buffalo Funds
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
	(a)   o
	(b)   þ
3	SEC USE ONLY
4	SOURCE OF FUNDS (SEE INSTRUCTIONS):
	Not Applicable
5	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
	o
6	CITIZENSHIP OR PLACE OF ORGANIZATION:
	United States
		7	SOLE VOTING POWER
NUMBER OF			0
SHARES		8	SHARED VOTING POWER
BENEFICIALLY
OWNED BY			See Item 5
EACH		9	SOLE DISPOSITIVE POWER
REPORTING
PERSON			395,000
WITH		10	SHARED DISPOSITIVE POWER
			0
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	See Item 5
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
	o
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
	See Item 5
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
	IC

1	NAMES OF REPORTING PERSONS: Harry Lowell
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
	(a)   o
	(b)   þ
3	SEC USE ONLY
4	SOURCE OF FUNDS (SEE INSTRUCTIONS):
	Not Applicable
5	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
	o
6	CITIZENSHIP OR PLACE OF ORGANIZATION:
	United States
		7	SOLE VOTING POWER
NUMBER OF			0
SHARES		8	SHARED VOTING POWER
BENEFICIALLY
OWNED BY			See Item 5
EACH		9	SOLE DISPOSITIVE POWER
REPORTING
PERSON			150,384
WITH		10	SHARED DISPOSITIVE POWER
			0
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	See Item 5
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
	o
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
	See Item 5
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
	IN

1	NAMES OF REPORTING PERSONS: Laurel Center Management Employee Profit Sharing Trust
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
	(a)   o
	(b)   þ
3	SEC USE ONLY
4	SOURCE OF FUNDS (SEE INSTRUCTIONS):
	Not Applicable
5	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
	o
6	CITIZENSHIP OR PLACE OF ORGANIZATION:
	United States
		7	SOLE VOTING POWER
NUMBER OF			0
SHARES		8	SHARED VOTING POWER
BENEFICIALLY
OWNED BY			See Item 5
EACH		9	SOLE DISPOSITIVE POWER
REPORTING
PERSON			129,457
WITH		10	SHARED DISPOSITIVE POWER
			0
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	See Item 5
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
	o
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
	See Item 5
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
	EP

1	NAMES OF REPORTING PERSONS: Adirondack Funds
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
	(a)   o
	(b)   þ
3	SEC USE ONLY
4	SOURCE OF FUNDS (SEE INSTRUCTIONS):
	Not Applicable
5	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
	o
6	CITIZENSHIP OR PLACE OF ORGANIZATION:
	United States
		7	SOLE VOTING POWER
NUMBER OF			0
SHARES		8	SHARED VOTING POWER
BENEFICIALLY
OWNED BY			See Item 5
EACH		9	SOLE DISPOSITIVE POWER
REPORTING
PERSON			61,000
WITH		10	SHARED DISPOSITIVE POWER
			0
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	See Item 5
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
	o
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
	See Item 5
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
	IC

1	NAMES OF REPORTING PERSONS: Matthew Reiner
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
	(a)   o
	(b)   þ
3	SEC USE ONLY
4	SOURCE OF FUNDS (SEE INSTRUCTIONS):
	Not Applicable
5	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
	o
6	CITIZENSHIP OR PLACE OF ORGANIZATION:
	United States
		7	SOLE VOTING POWER
NUMBER OF			0
SHARES		8	SHARED VOTING POWER
BENEFICIALLY
OWNED BY			See Item 5
EACH		9	SOLE DISPOSITIVE POWER
REPORTING
PERSON			1,675
WITH		10	SHARED DISPOSITIVE POWER
			0
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	See Item 5
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
	o
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
	See Item 5
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
	IN

1	NAMES OF REPORTING PERSONS: Brian D. Goe
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
	(a)   o
	(b)   þ
3	SEC USE ONLY
4	SOURCE OF FUNDS (SEE INSTRUCTIONS):
	Not Applicable
5	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
	o
6	CITIZENSHIP OR PLACE OF ORGANIZATION:
	United States
		7	SOLE VOTING POWER
NUMBER OF			0
SHARES		8	SHARED VOTING POWER
BENEFICIALLY
OWNED BY			See Item 5
EACH		9	SOLE DISPOSITIVE POWER
REPORTING
PERSON			75,000
WITH		10	SHARED DISPOSITIVE POWER
			0
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	See Item 5
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
	o
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
	See Item 5
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
	IN

1	NAMES OF REPORTING PERSONS: Paradigm Capital Management, Inc.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
	(a)   o
	(b)   þ
3	SEC USE ONLY
4	SOURCE OF FUNDS (SEE INSTRUCTIONS):
	Not Applicable
5	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
	o
6	CITIZENSHIP OR PLACE OF ORGANIZATION:
	United States
		7	SOLE VOTING POWER
NUMBER OF			0
SHARES		8	SHARED VOTING POWER
BENEFICIALLY
OWNED BY			See Item 5
EACH		9	SOLE DISPOSITIVE POWER
REPORTING
PERSON			660,360
WITH		10	SHARED DISPOSITIVE POWER
			0
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	See Item 5
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
	o
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
	See Item 5
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
	IA

1	NAMES OF REPORTING PERSONS: Johan Blok
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
	(a)   o
	(b)   þ
3	SEC USE ONLY
4	SOURCE OF FUNDS (SEE INSTRUCTIONS):
	Not Applicable
5	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
	o
6	CITIZENSHIP OR PLACE OF ORGANIZATION:
	United States
		7	SOLE VOTING POWER
NUMBER OF			0
SHARES		8	SHARED VOTING POWER
BENEFICIALLY
OWNED BY			See Item 5
EACH		9	SOLE DISPOSITIVE POWER
REPORTING
PERSON			55,000
WITH		10	SHARED DISPOSITIVE POWER
			0
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	See Item 5
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
	o
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
	See Item 5
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
	IN

1	NAMES OF REPORTING PERSONS: Goldman Partners, L.P.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
	(a)   o
	(b)   þ
3	SEC USE ONLY
4	SOURCE OF FUNDS (SEE INSTRUCTIONS):
	Not Applicable
5	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
	o
6	CITIZENSHIP OR PLACE OF ORGANIZATION:
	United States
		7	SOLE VOTING POWER
NUMBER OF			0
SHARES		8	SHARED VOTING POWER
BENEFICIALLY
OWNED BY			See Item 5
EACH		9	SOLE DISPOSITIVE POWER
REPORTING
PERSON			500,000
WITH		10	SHARED DISPOSITIVE POWER
			0
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	See Item 5
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
	o
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
	See Item 5
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
	PN

Item 1. Security and Issuer

     This statement relates to American Depository Shares of Trinity Biotech plc, a public limited company registered in Ireland (the “Company”), whose principal executive offices are located at IDA Business Park, Bray County, Wicklow, Ireland.

Item 2. Identity and Background

(a)-(c)	Schedule 13D is filed by Thomas J. Reidy, Buffalo Funds, Harry Lowell, Laurel Center Management Employee Profit Sharing Trust, Adirondack Funds, Matthew Reiner, Brian D. Goe, Paradigm Capital Management, Inc., Johan Blok and Goldman Partners, L.P. (collectively the “Reporting Persons”).
	The address and principal occupation of each of the Reporting Persons who is a natural person is:

		Present Principal
		Occupation or
Name	Residential or Principal Business Address	Employment
Thomas J. Reidy	211 May Apple Way Landrum, South Carolina 29356	Former CEO of diagnostic product manufacturing and distribution company
Harry Lowell	603 N. Lakeview Drive Ludington, Michigan 49431	Retired
Matthew Reiner	26 Vly Road Albany, New York 12205	Portfolio Manager Adirondack Research & Management, Inc. 26 Vly Road Albany, NY 12205
Brian D. Goe	725 River Road South Edgewater, New Jersey 07020	Partner B&D Construction 725 River Road South Edgewater, NJ 07020
Johan Blok	44 High Street #44 Perth Amboy, New Jersey 08861	General Manager Broadway Industries 53 Brunswick Ave. Edison, NJ 08817

The state of organization, principal business address and principal business of each entity is:

	State of
Name	Organization	Principal Business	Principal Business Address
Buffalo Funds	Delaware	Investment Company	5420 W. 61st Place Shawnee Mission, KS 66205
Laurel Center Management Employee Profit Sharing Trust	Michigan	Employee Benefit Plan	603 N. Lakeview Dr. Ludington, Michigan 49431
Adirondack Funds	Ohio	Investment Company	26 Vly Road Albany, NY 12205
Paradigm Capital Management, Inc.	New York	Investment Advisor	Nine Elk Street Albany, NY 12207
Goldman Partners, L.P.	New York	Private Investment Company	320 Park Avenue New York, NY

(d)	During the last five years, the Reporting Persons have not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
(e)	During the last five years, the Reporting Persons have not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and, as a result of such proceeding, been subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
(f)	All of the above natural persons are United States of America citizens.

Item 3. Source and Amount of Funds or Other Consideration.

     All the ADRs reported herein by the Reporting Persons were acquired by them using personal funds.

Item 4. Purpose of the Transaction.

     On September 26, 2008, Mr. Reidy signed and circulated to certain other Company shareholders a Request for Extraordinary General Meeting calling for the removal and replacement of the Company’s current directors. Between September 26, 2008 and October 6, 2008, Buffalo Funds, Harry Lowell, Laurel Center Management Employee Profit Sharing Trust, Adirondack Funds, Matthew Reiner, Brian D. Goe, Paradigm Capital Management, Inc. and Johan Blok executed and delivered to Mr. Reidy Joinders to the Request for Extraordinary General Meeting. Subsequent to October 6, 2008, Goldman Capital Partners executed and delivered to Mr. Reidy a Joinder to the Request for Extraordinary General Meeting. On October 16, 2008, Mr. Reidy sent the Request and Joinders referenced above to the Company. Under the rules promulgated under the Securities Exchange Act of 1934, all of the Reporting Persons may be deemed to be members of a group as a result of this collective action. However, each of the above Reporting Persons holds sole voting and dispositive powers with respect their stated number of ADRs. Accordingly, each Reporting Person disclaims membership in a group. Each Reporting Person originally acquired their ADRs of the Company for investment purposes. Each such Reporting Person’s interest is to maximize the value of his or its investment.

     The Reporting Persons signed the Request or a Joinder thereto for the purpose of consideration of changes to the current composition of the Company’s board of directors.

     Each Reporting Person may discuss with other ADR holders, shareholders, management, directors and other such persons their views concerning the removal and replacement of directors and other matters related to the Company. Each Reporting Person may continue to review the Company’s business affairs and financial position and future prospects, as well as conditions in the securities market and general economic conditions. Based on such evaluation and review and other factors, each Reporting Person may continue to consider various alternative courses of action and may in the future take such actions with respect to an investment in the Company as they each deem appropriate in light of the circumstances existing from time to time. Such actions may include seeking to acquire

control of the Company through a proxy solicitation or such other actions as each Reporting Person may deem appropriate. Such actions may involve the purchase of ADRs or underlying equity securities of the Company, or an alternative may involve the sale of all or a portion of the ADRs owned by them in the open market or in privately negotiated transactions to one or more purchasers. One or more of the Reporting Persons may, in the future, have influence over the corporate activities of the Company, including activities such as those described Subparagraphs (a) – (j) of Item 4 of Schedule 13D.

Item 5. Interest in Securities of the Issuer.

     NOTE: The percentages below are based on a total of 20,504,396 issued and outstanding shares of the Company’s American Depository Receipts. In its Form F-6 for the month of April 2008, the Company reported it had 18,689,191.25 shares of American Depository Receipts outstanding as of April 4, 2008. While the Company has not subsequently reported a change in this number, the Reporting Persons believe that the Company subsequently issued shares of ADRs causing 20,504,396 ADRs to now be issued and outstanding.

(a)-(c)	Mr. Reidy beneficially owns 101,000 shares of the Company’s ADRs. He has sole voting and dispositive powers with respect to such shares.
	Buffalo Funds beneficially owns 395,000 shares of the Company’s ADRs. It has sole voting and dispositive powers with respect to such shares.
	Mr. Lowell beneficially owns 150,384 shares of the Company’s ADRs. He has sole voting and dispositive powers with respect to such shares.
	Laurel Center Management Employee Profit Sharing Trust beneficially owns 129,457 shares of the Company’s ADRs. It has sole voting and dispositive powers with respect to such shares.
	Adirondack Funds beneficially owns 61,000 shares of the Company’s ADRs. It has sole voting and dispositive powers with respect to such shares.
	Mr. Reiner beneficially owns 1,675 shares of the Company’s ADRs. He has sole voting and dispositive powers with respect to such shares.
	Mr. Goe beneficially owns 75,000 shares of the Company’s ADRs. He has sole voting and dispositive powers with respect to such shares.
	Paradigm Capital Management, Inc. beneficially owns 660,360 shares of the Company’s ADRs. It has sole voting and dispositive powers with respect to such shares.
	Mr. Blok beneficially owns 55,000 shares of the Company’s ADRs. He has sole voting and dispositive powers with respect to such shares.
	Goldman Partners, L.P. beneficially owns 500,000 shares of the Company’s ADRs. It has sole voting and dispositive powers with respect to such shares.
(c)	Except for executing and delivering the Request or the Joinder (as the case may be), no reporting person has effected any transaction in the Company’s securities during the past 60 days, nor, to the best of their knowledge, has any affiliate of any Reporting Person effected any such transactions within the last 60 days.
(d)	Each Reporting Person retains the right to receive any dividends on the ADRs as well as any proceeds from the sale of the ADRs.
(e)	Not applicable.

     If the shareholders listed above are deemed to have acted together for the purpose of acquiring, holding, voting or disposing of equity securities of the Company (which the Reporting Persons disclaim), the ADR holders listed above, excluding Goldman Capital Partners, L.P., may be deemed to have acquired beneficial ownership as of October 6, 2008 of all of the 1,628,876 ADRs (or 7.94% of the issued and outstanding Company ADRs) owned by any such ADR holders. Likewise, the ADR holders listed above, including Goldman Capital Partners, L.P. may be deemed to have acquired beneficial ownership of all of the 2,128,876 ADRs (or 10.38% of the issued and outstanding Company ADRs) owned by such ADR holders as of the time Goldman Partners, L.P. executed and delivered its Joinder to Mr. Reidy. However, each Reporting Person denies that the power to vote or to direct the vote or to dispose of such person’s ADRs is shared with any other person or group of persons (including the Reporting Persons).

Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

     Although the Joinders of the Reporting Persons, excluding Goldman Capital Partners, L.P., were dated as of various dates prior to October 6, 2006, they were not all delivered to Mr. Reidy until October 6, 2008. Other than being signators to the Request or a Joinder thereto and the Joint Filing Agreement, the Reporting Persons are not aware of any other contract, arrangement, understanding or relationship to be disclosed under this Item 6.

Item 7. Material to be Filed as Exhibits.

Exhibit 1	Joint Filing Agreement among Thomas J. Reidy, Eric Ufer, Harry Lowell, Matthew Reiner, Brian D. Goe, Johan Blok, Buffalo Funds, Laurel Center Management Employee Profit Sharing Trust, Adirondack Funds, Paradigm Capital Management, Inc. and Goldman Partners, L.P.
Exhibit 2	Request for Extraordinary General Meeting dated September 26, 2008 signed by Thomas J. Reidy on his own behalf.
Exhibit 3	Joinder dated September 29, 2008 signed by Kent W. Gasaway on behalf of Buffalo Funds.
Exhibit 4	Joinder dated September September 26, 2008 signed by Harry Lowell on this own behalf and on behalf of the Laurel Center Management Employee Profit Sharing Trust as trustee
Exhibit 5	Joinder dated September 30, 2008 signed by Matthew P. Reiner on behalf of Adirondack Funds
Exhibit 6	Joinder dated September 30, 2008 signed by Matthew P. Reiner on his own behalf
Exhibit 7	Joinder dated October 1, 2008 signed by Brian D. Goe on his own behalf
Exhibit 8	Joinder dated September 29, 2008 signed by Candace Weir on behalf of Paradigm Capital Management, Inc.
Exhibit 9	Joinder dated October 2, 2008 signed by Johan Blok on his own behalf
Exhibit 10	Joinder dated October 7, 2008 signed by Neil I. Goldman on behalf of Goldman Partners, L.P.
Exhibit 11	Transmittal letter dated October 16, 2008 to Trinity Biotech plc (with schedule but without enclosures)

SIGNATURES

After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: October 16, 2008	By:	/S/ THOMAS J. REIDY
		Thomas J. Reidy
Dated: October 16, 2008	By:	/S/ HARRY M. LOWELL
		Harry M. Lowell
Dated: October 16, 2008	By:	/S/ MATTHEW P. REINER
		Matthew P. Reiner
Dated: October 16, 2008	By:	/S/ BRIAN D. GOE
		Brian D. Goe
Dated: October 16, 2008	By:	/S/ JOHAN BLOK
		Johan Blok

	BUFFALO FUNDS
Dated: October 16, 2008	/S/ KENT W. GASAWAY
	Name:	Kent W. Gasaway
	Title:	President

	LAUREL CENTER MANAGEMENT EMPLOYEE PROFIT SHARING TRUST
Dated: October 16, 2008	/S/ H. LOWELL
	Name:	H. Lowell
	Title:	Trustee

	ADIRONDACK FUNDS
Dated: October 16, 2008	/S/ MATTHEW P. REINER
	Name:	Matthew P. Reiner
	Title:	Portfolio Manager
	PARADIGM CAPITAL MANAGEMENT, INC.
Dated: October 16, 2008	/S/ CANDICE WEIR
	Name:	Candice Weir
	Title:	President and Chief Investment Officer
	GOLDMAN PARTNERS, L.P.
Dated: October 16, 2008	/S/ NEIL I. GOLDMAN
	Name:	Neil I. Goldman
	Title:	General Partner

EX-99.1

Exhibit 1

JOINT FILING AGREEMENT and

POWER OF ATTORNEY

     The undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including any amendments thereto) with respect to the American Depository Receipts of Trinity Biotech plc beneficially owned by each of them to the extent that they may be deemed to be acting as a group, and further agree that this Joint Filing Agreement be included as an exhibit to such joint filings. The undersigned further agree that each of them is (i) individually eligible to use the Schedule 13D to which this Exhibit is attached and (ii) responsible for the timely filing of such Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness of accuracy of the information concerning any other person making the filing, unless such person knows or has reason to believe that such information is inaccurate. This Joint Filing Agreement may be executed in any number of counterparts all of which taken together will constitute one and the same instrument.

     Each of the undersigned constitutes and appoints Thomas J. Reidy as his or its true and lawful attorney-in-fact and agent, with full power of substitution and resubmission, for him or it and in his or its name, place or stead, in any and all capacities to sign any or all amendments to this Schedule 13D filed under the Securities Exchange Act of 1934, as amended, and to file the same, with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in or about the premises, as fully to all intents and purposes as he or it might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     IN WITNESS THEREOF, the undersigned have executed this Joint Filing Agreement as of the date(s) set forth below.

Dated: October 16, 2008	By:	/S/ THOMAS J. REIDY
		Thomas J. Reidy
Dated: October 16, 2008	By:	/S/ HARRY M. LOWELL
		Harry M. Lowell
Dated: October 16, 2008	By:	/S/ MATTHEW P. REINER
		Matthew P. Reiner
Dated: October 16, 2008	By:	/S/ BRIAN D. GOE
		Brian D. Goe
Dated: October 16, 2008	By:	/S/ JOHAN BLOK
		Johan Blok
	BUFFALO FUNDS
Dated: October 16, 2008	/S/ KENT W. GASAWAY
	Name:	Kent W. Gasaway
	Title:	President

	LAUREL CENTER MANAGEMENT EMPLOYEE PROFIT SHARING TRUST
Dated: October 16, 2008	/S/ H. LOWELL
	Name:	H. Lowell
	Title:	Trustee
	ADIRONDACK FUNDS
Dated: October 16, 2008	/S/ MATTHEW P. REINER
	Name:	Matthew P. Reiner
	Title:	Portfolio Manager
	PARADIGM CAPITAL MANAGEMENT, INC.
Dated: October 16, 2008	/S/ CANDICE WEIR
	Name:	Candice Weir
	Title:	President and Chief Investment Officer
	GOLDMAN PARTNERS, L.P.
Dated: October 16, 2008	/S/ NEIL I. GOLDMAN
	Name:	Neil I. Goldman
	Title:	General Partner

EX-99.2

EXHIBIT 2

September 26, 2008

To the Secretary of Trinity Biotech, plc
IDA Business Park
Bray, Co.
Wicklow, Ireland

REQUEST FOR EXTRAORDINARY GENERAL MEETING

     The undersigned holders of American Depositary Receipts (“ADRs”) of Trinity Biotech plc (the “Company”), hereby request the calling of an Extraordinary General Meeting of Company shareholders to consider the following Ordinary Resolution:

     BE IT RESOLVED that the following individuals be removed as Directors of the Board of Directors of the Company, in accordance with the procedures set forth in Section 94 of the Articles of Association of the Company:

Ronan O’Caoimh
Brendan K. Farrell
Rory Nealon
Jim Walsh
Denis R. Burger
Peter Coyne

     and that the following individuals be appointed in their places:

Thomas J. Reidy
Jack C. Chow
Steven S. Mock
John H. Halsey
Mike Gausling

     The undersigned ADR Holders further direct that the Company shareholders be given prompt written notice (the “Meeting Notice”) of the Extraordinary General Meeting so called at least 28 clear days prior to the date set for the meeting and that the Meeting Notice be promptly sent to the Bank of New York Mellon, as depositary (the “Depositary”) under the Deposit Agreement dated as of October 21, 1992 among the Company, the Depositary and the owners and holders of the ADRs. Concurrently with the sending of the Meeting Notice to the Depositary, the Company shall request in writing that the Depositary shall, as soon as practicable thereafter, mail to the owners of the ADRs a notice which shall contain (a) such information as is contained in such notice of meeting and (b) a statement that the owners of the ADRs will be entitled to instruct the Depositary as to the exercise of voting rights pertaining to the amount of shares of deposited share of the Company represented by the respective American Depositary Shares evidenced by their ADRs.

ADR Holder:
By:	/s/ THOMAS J. REIDY
	THOMAS J. REIDY
And by those additional ADR Holders executing and delivering a Joinder.

EX-99.3

EXHIBIT 3

JOINDER

     Reference is made to that Request for Extraordinary General Meeting dated as of September 26, 2008 to the Secretary of Trinity Biotech, plc.

     By executing and delivering this Joinder, the undersigned holder of American Depository Receipts of Trinity Biotech, plc hereby becomes a signator to the Request for Extraordinary General Meeting as if the undersigned were an original signator to such document.

     The undersigned has executed and delivered this Joinder as of this 29^th day of 2008.

	Buffalo Funds
	Name of ADR Holder (type or print)
By:	/s/ Kent W. Gasaway
	Sign Name
	Kent W. Gasaway
	Name of Signator (type or print)
	President
	Capacity (type or print)

EX-99.4

EXHIBIT 4

JOINDER

     Reference is made to that Request for Extraordinary General Meeting dated as of September 26, 2008 to the Secretary of Trinity Biotech, plc.

     By executing and delivering this Joinder, the undersigned holder of American Depository Receipts of Trinity Biotech, plc hereby becomes a signator to the Request for Extraordinary General Meeting as if the undersigned were an original signator to such document.

     The undersigned has executed and delivered this Joinder as of this 26 day of September, 2008.

	HARRY M. LOWELL
	Name of ADR Holder (type or print)
By:	/s/ Harry M. Lowell
	Sign Name
	Harry M. Lowell
	Name of Signator (type or print)
	Capacity (type or print)

Scottrade Acct. #52700715:

Laurel Center Management Employee Profit Sharing Trust — 129,457 ADR Shares
H. Lowell, Trustee

Scottrade Acct. #52702852:

Harry M. Lowell (Personal) — 150,384 ADR Shares

EX-99.5

EXHIBIT 5

JOINDER

     Reference is made to that Request for Extraordinary General Meeting dated as of September 26, 2008 to the Secretary of Trinity Biotech, plc.

     By executing and delivering this Joinder, the undersigned holder of American Depository Receipts of Trinity Biotech, plc hereby becomes a signator to the Request for Extraordinary General Meeting as if the undersigned were an original signator to such document.

     The undersigned has executed and delivered this Joinder as of this 30^th day of September, 2008.

	Adirondack Funds
	Name of ADR Holder (type or print)
By:	/s/ Matthew P. Reiner
	Sign Name
	Matthew P. Reiner
	Name of Signator (type or print)
	Portfolio Manager
	Capacity (type or print)

EX-99.6

EXHIBIT 6

JOINDER

     Reference is made to that Request for Extraordinary General Meeting dated as of September 26, 2008 to the Secretary of Trinity Biotech, plc.

     By executing and delivering this Joinder, the undersigned holder of American Depository Receipts of Trinity Biotech, plc hereby becomes a signator to the Request for Extraordinary General Meeting as if the undersigned were an original signator to such document.

     The undersigned has executed and delivered this Joinder as of this 30^th day of September, 2008.

	Matthew P. Reiner
	Name of ADR Holder (type or print)
By:	/s/ Matthew P. Reiner
	Sign Name
	Matthew P. Reiner
	Name of Signator (type or print)
	Capacity (type or print)

EX-99.7

EXHIBIT 7

JOINDER

     Reference is made to that Request for Extraordinary General Meeting dated as of September 26, 2008 to the Secretary of Trinity Biotech, plc.

     By executing and delivering this Joinder, the undersigned holder of American Depository Receipts of Trinity Biotech, plc hereby becomes a signator to the Request for Extraordinary General Meeting as if the undersigned were an original signator to such document.

     The undersigned has executed and delivered this Joinder as of this 1 day of October, 2008.

	BRIAN DAVID GOE
	Name of ADR Holder (type or print)
By:	/s/ Brian David Goe
	Sign Name
	BRIAN DAVID GOE
	Name of Signator (type or print)
	Capacity (type or print)

EX-99.8

EXHIBIT 8

JOINDER

     Reference is made to that Request for Extraordinary General Meeting dated as of September 26, 2008 to the Secretary of Trinity Biotech, plc.

     By executing and delivering this Joinder, the undersigned holder of American Depository Receipts of Trinity Biotech, plc hereby becomes a signator to the Request for Extraordinary General Meeting as if the undersigned were an original signator to such document.

     The undersigned has executed and delivered this Joinder as of this 29 day of September, 2008.

Paradigm Capital Management
Name of ADR Holder (type or print)
By:	/s/ Candace Weir
	Sign Name
Candace Weir
Name of Signator (type or print)
President and Chief Investment Officer
Capacity (type or print)

EX-99.9

EXHIBIT 9

JOINDER

     Reference is made to that Request for Extraordinary General Meeting dated as of September 26, 2008 to the Secretary of Trinity Biotech, plc.

     By executing and delivering this Joinder, the undersigned holder of American Depository Receipts of Trinity Biotech, plc hereby becomes a signator to the Request for Extraordinary General Meeting as if the undersigned were an original signator to such document.

     The undersigned has executed and delivered this Joinder as of this 2nd day of October, 2008.

Johan Blok
Name of ADR Holder (type or print)
By:	/s/ Johan Blok
	Sign Name
Johan Blok
Name of Signator (type or print)
Owner of 55,000 ADRs
Capacity (type or print)

EX-99.10

EXHIBIT 10

JOINDER

     Reference is made to that Request for Extraordinary General Meeting dated as of September 26, 2008 to the Secretary of Trinity Biotech, plc.

     By executing and delivering this Joinder, the undersigned holder of American Depository Receipts of Trinity Biotech, plc hereby becomes a signator to the Request for Extraordinary General Meeting as if the undersigned were an original signator to such document.

     The undersigned has executed and delivered this Joinder as of this 7 day of October, 2008.

GOLDMAN PARTNERS, L.P.
Name of ADR Holder (type or print)
By:	/s/ Neal Goldman
	Sign Name
Neal Goldman
Name of Signator (type or print)
General Partner
Capacity (type or print)

EX-99.11

EXHIBIT 11

Thomas J. Reidy
211 May Apple Way
Landrum, SC 29356

October 16, 2008

BY FAX 353 1-276-9888
UNITED STATES MAIL

To the Secretary of Trinity Biotech, plc
IDA Business Park
Bray, Co.
Wicklow, Ireland

          Re:     Request for Extraordinary General Meeting

Dear Sir:

     As an owner of American Depository Receipts (“ADRs”) of Trinity Biotech plc (the “Company”), I have become increasingly concerned about the Company’s business affairs and financial performance and management capabilities. In addition, I consider the Company’s repeated failure to timely notify its ADR holders of shareholder meetings of the Company as a management entrenchment device carried out at the expense of the shareholders’ interest in fostering management accountability.

     I enclose a Request for Extraordinary General Meeting (the “Request”) calling for the removal and replacement of the current directors (the “Proposal”). You will also find enclosed Joinders to the Request that have been executed and delivered by nine additional ADR holders.

     Biographical information concerning replacement directors named in the Proposal is attached hereto as Schedule 1. If the replacement directors are installed, I intend to recommend to the new directors that Clint Severson be appointed as the sixth director. Mr. Severson’s biographical information is also included on Schedule 1.

     The nine additional ADR holders and myself (collectively the “Requesting ADR Holders”) beneficially own 8,515,504 A Ordinary Shares of the Company. Based on outstanding voting share amounts reported by the Company in its filings with the United States Securities and Exchange Commission, the Requesting ADR Holders collectively beneficially own in excess of one-tenth of the voting paid up capital of the Company and the minimum amount required under Irish Law for shareholders to requisition a Extraordinary General Meeting

     Having met the requirements for the requisition of a shareholders meeting under Irish Law, we direct that the directors set a date, time and place for the Extraordinary General Meeting for the purpose of acting on the Proposal and that shareholders be provided notice of the

To the Secretary of Trinity Biotech plc
October 16, 2008
Page 2

Extraordinary General Meeting in sufficient time to be able to exercise their voting rights effectively.

     We further direct that the meeting notice be promptly sent to the Bank of New York Mellon, as the depository under the Deposit Agreement dated as of October 21, 1992, as amended and restated as of                     , 2004, among the Company, the depository and the owners and holders of the ADRs. Concurrently with the sending of the meeting notice to the depository, we direct that the Company request in writing that the depository shall, as soon as practical thereafter, mail to all ADR holders a notice which shall contain (i) such information as is contained in such notice of meeting and (ii) a statement that the owners of the ADRs will be entitled to instruct the depository as to the exercise of voting rights pertaining to the amount of shares of deposited shares of the Company evidenced by their ADRs.

     To ensure that all beneficial owners of the ADRs receive notice of the Extraordinary General Meeting, the depository should be directed to instruct banks and brokers that hold ADRs in street name on behalf of their clients to forward, within five business days, the notice and instructions to the beneficial owners of the ADRs.

     If management disputes the claim of the Requesting ADR Holders that they collectively beneficially own in excess of one-tenth of the voting paid up capital of the Company, we request that you advise the undersigned of the basis of management’s position, including the amount of Company voting shares, by class, currently outstanding and the par value of each such share stated in U.S. dollars.

     If management of the Company is of the opinion that the Requesting ADR Holders do not have the authority to request the meeting (because they do not hold the underlying A Ordinary Shares), we request that you advise the undersigned immediately in writing of such a determination.

     In the event of such a determination, we request that the directors, on their own volition, immediately call and notice up (in the manner specified above) an Extraordinary General Meeting of shareholders for the purpose of the consideration of the Proposal. In this manner, the Requesting ADR Holders will be alleviated the hardship and inconvenience of converting their ADRs to A Ordinary Shares for the sole purpose of exercising their shareholder rights.

     Alternatively, we request that the directors immediately take steps to amend the Depository Agreement solely to permit ADR holders to cause the depository to make proposals on their behalf to the same extent as holders of A Ordinary Shares are permitted under applicable Irish law and the Company’s Articles of Association.

     Management’s refusal to honor the Request or to take the alternative steps proposed above to bring the Proposal before the Company’s shareholders can only be viewed as a further step by management to remain entrenched in their positions and beyond any accountability to the owners of the Company.

To the Secretary of Trinity Biotech plc
October 16, 2008
Page 3

     If you have any questions regarding the Request or if you need additional information with respect the holdings of the Requesting ADR holders, please advise the undersigned by writing or calling the undersigned at 01-816-260-8476.

Sincerely,

/s/ THOMAS J REIDY

Thomas J. Reidy

TJR:WMS:dgh
Enclosures

SCHEDULE 1

     Jack C. Chow, M.D.

          Former US Ambassador Jack Chow is a partner in CRV Capital, LLC, a multi-strategy investment entity, and an adjunct faculty member at Carnegie Mellon University’s Heinz School of Public Policy and Management. In public service, he held pioneering roles in global public health. He was the first Director-General of the World Health Organization responsible for HIV/AIDS-Tuberculosis-Malaria and was the Special Envoy of WHO’s Director General, based in Washington, D.C. Prior to serving at WHO, Dr. Chow was the Special Representative of the Secretary of State, Colin L. Powell for global HIV/AIDS and was the first Ambassador Rank diplomat at the State Department appointed to a global health mission. His extensive government experience includes working with the Senate and House Appropriation Committees, the NIH, the Department of Health and Human Services, and the White House Science Office. He has also worked in the private sector as a management consultant to McKinsey and Company. He earned his medical degree at the University of California at San Francisco and trained at Stanford University Hospital. In addition, Dr. Chow holds other degrees from Harvard’s Kennedy School of Government (MPA), University of Chicago business school (MBA), Berkeley’s School of Public Health (BS), and a BA from the University of Pennsylvania.

     Mike Gausling

          Mike was the founder and former CEO of Orasure Technologies, (NASDAQ: OSUR) and helped build the company to a market cap of over $500M during his tenure. Mike was recognized as Biotech Entrepreneur of the year and head of one of the top seven growth companies in the greater Philadelphia area. Mike has also served as Audit Chair for KNBT Bancorp, (NASDAQ: KNBT) which has grown to over $3B in assets. Mike currently serves on the Life Sciences Advisory Board for Safeguard Scientifics, Inc. (NYSE: SFE), a holding company that builds value in high-growth revenue stage information technology and life science businesses. Mike is also current treasurer of LVIP, a non-profit development company investing $100 million in viable re-development of prime real estate. Mike received has degrees from Rensselaer Polytechnic Institute (BS) and Miami University of Ohio (MBA).

     John H. “Jack” Halsey, Ph.D.

          Chief Executive Officer, Director and Founder, ProGene Biomedical, Inc. (dba IBT Laboratories) Jack has served on the Scientific Advisory Board member for Oncimmune, LLC; and as a Consultant to the Food & Drug Administration, Immunology Devices Panel. In addition, Jack has performed as an Advisor to the Clinical & Laboratory Standards Institute (formerly NCCLS) as well as an Advisor to the College of American Pathologists Pathology Coding Caucus. He is currently Clinical Associate Professor at the Department of Medicine, Division of Allergy, Immunology and Rheumatology, University of Kansas School of Medicine. Jack was a Previous Director for ImmunoNuclear Corporation, Inc, ImmuneTech, Inc. and Research Think Tank, Inc.

          Jack served as Associate Professor (with tenure), and Assistant Professor (1978-1982), Department of Biochemistry and Molecular Biology, University of Kansas School of

Medicine, Kansas City, KS. In addition, he held the post of Assistant Professor, Department of Microbiology, University of Oklahoma, Norman, OK. Jack did his Post-Doctoral Fellowship and served as an Instructor at the Medical University of South Carolina, Charleston, SC.and the University Of Virginia School Of Medicine, Charlottesville, VA. Jack received his degrees from The Johns Hokins University (Ph.D. in Biochemistry), and the University of Florida (B.S. in Chemistry and M.S. in Medical Microbiology).

     Steven S. Mock, CPA

          Steve is a current Partner in BKD, LLP, one of America’s top ten CPA and advisory firms, and the regions’ largest accounting company. In addition to his tax expertise, Steve specializes in strategic business planning, and tactical execution, as well as business valuation and business succession planning for corporate clients. Steve has over 30 years experience with companies providing tax and planning services, and served as CFO of a local medical device manufacturer, prior to its sale. Before merging with B.K.D., Steve was co-founder and managing partner of Mock and Dackan, P.C. Steve did his undergraduate work at the University of Missouri and holds a B.S. in both accounting and finance.

     Thomas J. Reidy

          With over 35 years experience in the IVD business, Tom has extensive experience in management, sales and distributor relationships, both Domestic and International. As founder of Primus, an acquired company of Trinity, Tom was responsible for overseeing the development, patenting, regulatory licensing, production, introduction, and sales of new but well-accepted diagnostic assays. His previous experience in both reference laboratory and diagnostic companies gave him the broad interaction with other industry leaders that helps facilitate successful partnering and joint venturing as needed. His company was able to maintain high sales/employee, as well as double-digit growth percentages and net income while keeping one of the lowest personnel turnover rates in the industry. His ability to manage diverse elements of the company and bring them together as a team will be essential to the success of Trinity. Tom did his undergraduate work at the University of Indiana and completed his MBA course work at Ohio State University.

     Clint Severson

          Raised in Minot, North Dakota, Clint Severson received his Bachelors of Business Administration from Minot State University in 1973. Upon graduation, he moved to San Francisco and began his career in diagnostics sales and management with Dow Chemical where he sold blood-testing equipment. He spent the next 11 years discovering his true calling for growing development stage companies into profitable businesses from: 1978-1984 — Syva, 1984-1989 — 3M Diagnostic Systems, 1989-1996 — Mast Immunosystems, and 1996-Present — Abaxis, Inc.

          As the current Chairman, President & CEO of Abaxis, Clint took the late developmental stage, NASDAQ traded company, with annual sales of $2.9 million and annual loss of $6.7 million and grew sales at a 34% compounded annual growth rate to over $100 million per year and an operating profit of $17.8 million. Clint’s achievements were recognized by Forbes Magazine as Entrepreneur of the Year and ranked Abaxis 11 of 200 best small companies.